Neovascular Age-related Macular Degeneration
Showing 1 - 25 of 145
Neovascular Age-related Macular Degeneration Trial (RRG001)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- (no location specified)
Nov 15, 2023
Single Injection of Faricimab for nAMD With Persisting Fluid
Active, not recruiting
- Neovascular Age-related Macular Degeneration
-
Glostrup, DenmarkMiklos Schneider
Nov 3, 2023
Patterns With Brolucizumab in Germany -Retrospective Cohort
Completed
- Neovascular Age-related Macular Degeneration
-
Porto Salvo, PortugalNovartis
Aug 28, 2023
Neovascular Age-related Macular Degeneration Trial in Katy, Norfolk (SKG0106)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- SKG0106
-
Katy, Texas
- +1 more
Aug 15, 2023
Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- Aflibercept Ophthalmic
- IBI302
-
Suzhou, Jiangsu, ChinaInnovent Biologics (Suzhou) Co,Ltd.
Jul 25, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Beijing (Intravitreal injection of IBI302(dose 1),
Suspended
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
- Intravitreal injection of IBI302(dose 1)
- +3 more
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jul 17, 2023
Neovascular Age-related Macular Degeneration Trial (PMC-403)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- (no location specified)
Jul 11, 2023
Neovascular Age-related Macular Degeneration Trial in Graz (Aflibercept 40 MG/ML, Faricimab 120 MG/ML)
Recruiting
- Neovascular Age-related Macular Degeneration
- Aflibercept 40 MG/ML
- Faricimab 120 MG/ML
-
Graz, Styria, AustriaDepartment of Ophthalmolgy, Medical University Graz
Jul 3, 2023
Neovascular Age-related Macular Degeneration Trial (Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule,
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule
- Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule
- (no location specified)
Jun 6, 2023
Neovascular Age-related Macular Degeneration Trial in Phoenix (CLS-AX, Aflibercept)
Recruiting
- Neovascular Age-related Macular Degeneration
-
Phoenix, ArizonaRetinal Research Institute, LLC
Jun 4, 2023
Neovascular Age-related Macular Degeneration Trial (AXT107 Low Dose, AXT107 Mid Dose, AXT107 High Dose)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- AXT107 Low Dose
- +2 more
- (no location specified)
May 5, 2023
Neovascular Age-related Macular Degeneration Trial in Shanghai (LX102-C01 Injection)
Active, not recruiting
- Neovascular Age-related Macular Degeneration
- LX102-C01 Injection
-
Shanghai, ChinaShanghai General Hospital, Shanghai Jiao Tong University School
Apr 14, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Austin (AIV007)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
-
Austin, TexasRetina Consultants of Austin
Jan 16, 2023
Neovascular Age-related Macular Degeneration Trial in Worldwide (SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL))
Active, not recruiting
- Neovascular Age-related Macular Degeneration
- SOK583A1 (40 mg/mL)
- Eylea EU (40 mg/mL)
-
Phoenix, Arizona
- +101 more
Jan 23, 2023
Neovascular Age-related Macular Degeneration Trial in Worldwide (brolucizumab)
Active, not recruiting
- Neovascular Age-related Macular Degeneration
-
Huntington Beach, California
- +59 more
Jan 20, 2023
Neovascular Age-Related Macular Degeneration Trial in China (Brolucizumab 6mg, Aflibercept 2 mg)
Recruiting
- Neovascular Age-Related Macular Degeneration
- Brolucizumab 6mg
- Aflibercept 2 mg
-
Guangzhou, Guangdong, China
- +30 more
Jan 20, 2023
Russian Registry of Patients With nAMD
Terminated
- Neovascular Age-Related Macular Degeneration
- nAMD
- (no location specified)
Jan 16, 2023
Neovascular Age-related Macular Degeneration Trial in United States (SUSVIMO (ranibizumab injection), LUCENTIS (ranibizumab
Recruiting
- Neovascular Age-related Macular Degeneration
- SUSVIMO (ranibizumab injection)
- LUCENTIS (ranibizumab injection)
-
Mesa, Arizona
- +32 more
Jan 13, 2023
Neovascular Age-related Macular Degeneration Trial in United States (OLX10212 is a cell penetrating asymmetric small
Recruiting
- Neovascular Age-related Macular Degeneration
- OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
-
Santa Maria, California
- +4 more
Jan 10, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in San Antonio (D-4517.2)
Recruiting
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
-
Los Angeles, California
- +11 more
Jan 11, 2023
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Mesa, Phoenix (Faricimab PFS Configuration)
Completed
- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema
- Faricimab PFS Configuration
-
Mesa, Arizona
- +2 more
Jan 2, 2023
Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study
Active, not recruiting
- Neovascular Age-related Macular Degeneration
-
Phoenix, Arizona
- +6 more
Dec 14, 2022
Neovascular Age-related Macular Degeneration Trial in Beijing (IBI333)
Not yet recruiting
- Neovascular Age-related Macular Degeneration
- IBI333
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital, Chinese Academy of Medica
Nov 28, 2022